NASDAQ:CFRX - ContraFect Stock Price, Forecast & News

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

Shares of ContraFect reverse split on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2020. An investor that had 100 shares of ContraFect stock prior to the reverse split would have 10 shares after the split.

ContraFect Corp (NASDAQ:CFRX) issued its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.77) by $0.07. View ContraFect's Earnings History.

ContraFect is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for ContraFect.

2 equities research analysts have issued 1 year target prices for ContraFect's shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate ContraFect's share price to reach $17.50 in the next year. This suggests a possible upside of 76.2% from the stock's current price. View Analyst Price Targets for ContraFect.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraFect.

News articles about CFRX stock have been trending extremely negative recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ContraFect earned a media sentiment score of -4.9 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for ContraFect.

ContraFect saw a decline in short interest during the month of February. As of February 14th, there was short interest totalling 328,100 shares, a decline of 64.1% from the January 30th total of 914,700 shares. Based on an average trading volume of 192,800 shares, the short-interest ratio is currently 1.7 days. Approximately 2.6% of the company's shares are short sold. View ContraFect's Current Options Chain.

Some companies that are related to ContraFect include G1 Therapeutics (GTHX), Omeros (OMER), Vectura Group (VEGPF), Akero Therapeutics (AKRO), Basilea Pharmaceutica (BPMUF), Cara Therapeutics (CARA), Molecular Templates (MTEM), Provention Bio (PRVB), Flexion Therapeutics (FLXN), RAPT Therapeutics (RAPT), Retrophin (RTRX), Urogen Pharma (URGN), Endonovo Therapeutics (ENDV), Vanda Pharmaceuticals (VNDA) and Atreca (BCEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Catalyst Pharmaceuticals (CPRX), Antares Pharma (ATRS), Inovio Pharmaceuticals (INO), Edge Therapeutics (EDGE), Nabriva Therapeutics (NBRV), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), Cara Therapeutics (CARA) and Corbus Pharmaceuticals (CRBP).

ContraFect's stock is owned by many different of retail and institutional investors. Top institutional investors include Birchview Capital LP (18.44%), Oracle Investment Management Inc. (9.80%), Renaissance Technologies LLC (6.80%), Trellus Management Company LLC (3.91%), AMG National Trust Bank (0.05%) and Sheaff Brock Investment Advisors LLC (0.03%). Company insiders that own ContraFect stock include Cary Sucoff, Fosun Pharmaceutical Shanghai and Michael Messinger. View Institutional Ownership Trends for ContraFect.

CFRX stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc.. View Insider Buying and Selling for ContraFect.

CFRX stock was acquired by a variety of institutional investors in the last quarter, including Birchview Capital LP, Renaissance Technologies LLC, Trellus Management Company LLC, AMG National Trust Bank and Sheaff Brock Investment Advisors LLC. Company insiders that have bought ContraFect stock in the last two years include Cary Sucoff and Michael Messinger. View Insider Buying and Selling for ContraFect.

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CFRX stock can currently be purchased for approximately $9.93.

ContraFect has a market capitalization of $152.25 million. The biotechnology company earns $-37,680,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. ContraFect employs 20 workers across the globe.View Additional Information About ContraFect.

The official website for ContraFect is http://www.contrafect.com/.

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]